---
title: "Why Is Aclarion Stock (ACON) Up Today?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271937867.md"
description: "Aclarion (ACON) stock surged 54.09% in pre-market trading after the company provided a corporate update and financial guidance for 2026, including plans for nine new imaging centers and 22 new physician users. The company reported advancements in its Nociscan platform, strengthened clinical evidence, and ongoing evaluations for growth opportunities. Despite a 25% year-to-date increase, ACON has fallen 99.46% over the past year. Heavy trading occurred with nearly 10 million shares exchanged, compared to a three-month average of 272,000 shares."
datetime: "2026-01-08T13:03:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271937867.md)
  - [en](https://longbridge.com/en/news/271937867.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271937867.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271937867.md) | [繁體中文](https://longbridge.com/zh-HK/news/271937867.md)


# Why Is Aclarion Stock (ACON) Up Today?

Aclarion (ACON) stock rocketed higher Thursday after the healthcare technology company provided a corporate update and financial guidance for 2026. This includes strong growth in 2025, with the opening of nine new imaging centers and the addition of 22 new physician users. The company also expanded its leadership team in the U.S. and UK.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Diving into Aclarion's operations, the company reported:

-   Continued advancement of its Nociscan platform
-   A strengthened clinical evidence base
-   Expanded engagement with healthcare providers and payors
-   Disciplined capital management
-   Ongoing evaluation of strategic partnerships and growth opportunities
-   A bolstered intellectual property footprint

Looking to 2026, the company said it expects several positive catalysts. Among them are enrolling approximately 25% of patients in the CLARITY trial by the end of Q2 2026, completing and publishing multiple investigator-initiated real world evidence trials, and expanding major MRI manufacturer access to grow the available global market size by more than 30%.

## **Aclarion Stock Movement Today**

Aclarion stock was up 54.09% in pre-market trading on Thursday, following a 7.08% rally yesterday. The stock was up 25% year-to-date but has fallen 99.46% over the past 12 months.

ACON stock experienced heavy trading on Thursday, as nearly 10 million shares changed hands. For comparison, the stock's three-month daily average trading volume is about 272,000 units.

### Related Stocks

- [Aclarion, Inc. (ACON.US)](https://longbridge.com/en/quote/ACON.US.md)

## Related News & Research

- [Aclarion Announces $10.4 Million Registered Direct Offering](https://longbridge.com/en/news/272091929.md)
- [Global Net Lease Declares Q2 2026 Common Dividend](https://longbridge.com/en/news/281364010.md)
- [07:29 ETSMR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds NuScale (SMR) Investors of Securities Class Action Deadline on April 20, 2026](https://longbridge.com/en/news/281683966.md)
- [Bright Path Applauds Presidential Proclamation Imposing Tariffs on Imported Pharmaceuticals](https://longbridge.com/en/news/281585445.md)
- [Huntington declares preferred dividends for Series I and Series L](https://longbridge.com/en/news/281079431.md)